Platelet Aggregate Ratio in Diabetes mellitus

Jw, Davis; Cr, Hartman; Rf, Davis; Jl, Kyner; Hd, Lewis; Pe, Phillips

doi:10.1159/000207062

Cited by 14 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The platelet alterations that occur in diabetes have been extensively studied. An increased platelet aggregation has been reported in Type 1 (insulin-dependent) diabetic patients with poor metabolic control [34]. This phenomenon is accompanied by an increase in the circulating levels of some indices of platelet activation such as fl-thromboglobulin [35] and platelet factor 4 [36].…”

Section: Plateletsmentioning

confidence: 98%

Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects

1993

View full text Add to dashboard Cite

Numerous studies have shown that coagulation abnormalities occur in the course of diabetes mellitus, resulting in a state of thrombophilia. These observations are supported by epidemiological studies which demonstrate that thromboembolic events are more likely to occur in diabetic patients. The coagulation abnormalities observed in diabetic patients seem to be caused by the hyperglycaemia, which also constitutes the distinguishing feature of this disease. These data are also supported by in vitro studies which demonstrate how glucose can directly determine alterations in the coagulation system. The abnormalities observed involve all stages of coagulation, affecting both thrombus formation and its inhibition, fibrinolysis, platelet and endothelial function. The final result is an imbalance between thrombus formation and dissolution, favouring the former. Hyperglycaemia probably determines the onset of these abnormalities through three mechanisms which are, respectively, non-enzymatic glycation, the development of increased oxidative stress and a decrease in the levels of heparan sulphate. The first seems to affect the functionality of key molecules of coagulation in a negative sense. Oxidative stress constitutes an important pro-thrombotic stimulus, while the decrease in heparan sulphate determines a reduction in antithrombotic defenses. Good metabolic control could play a key role in controlling the coagulation irregularities in diabetes. However, considering the difficulties in achieving such an objective, it is possible that the use of drugs may represent a valid alternative. In fact, several drugs exist which are of potential interest. It is, however, necessary to perform long-term studies which demonstrate unequivocably that by controlling the coagulation abnormalities in diabetic patients, prolongation of life is possible.

show abstract

Section: Plateletsmentioning

confidence: 98%

Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects

1993

View full text Add to dashboard Cite

show abstract

“…Many authors have assessed the state of platelet activation in several clinical con ditions such as diabetes mellitus [7], acute myocardial infarction [5], arterial insuffi ciency [4], ischaemic heart disease [6] and transient ischaemic attacks [9]. As indices of platelet activation in vivo, they consid ered various parameters, such as the PAR, expression of existence of circulating mi croaggregates, the ft-tg level, /tog being a platelet-specific protein which is secreted by the a-granules into the bloodstream during the release reaction, the PF4, hav ing a structure and significance similar to that of P-tg but a slightly different behav iour [3,18] malondialdehyde (MDA) pro duction, reflecting prostaglandin/thromboxane synthesis, and others.…”

Section: Discussionmentioning

confidence: 99%

“…Many investigators have attempted to measure the levels of these specific mark ers of in vivo platelet release reaction and to identify and quantify the presence of microaggregates in different clinical con ditions, such as myocardial infarction [5,6], diabetes mellitus [7], arterial insuffi ciency [4][5][6][7][8], transient ischaemic attacks [9], deep vein thrombosis [10,11] and others [12].…”

Section: Introductionmentioning

confidence: 99%

In vivo Platelet Activation in Lower Limbs Thrombophlebitis

Bazzan¹,

Pannocchia²,

Schinco³

et al. 1984

Acta Haematol

View full text Add to dashboard Cite

Platelet activation in vivo was studied in patients with thrombophlebitis of the lower limbs. The parameters considered were the platelet aggregate ratio (PAR) and the β-thromboglobulin (β-tg) level, which were repeatedly evaluated from the disease onset up to 3 months later, during anticoagulating and antiaggregating therapy. A significant decrease of PAR was found, along with a significant rise of the β-tg level at the onset of the disease, and these values slowly returned to normal on therapy course. The same parameters exceeded the normal range again when the patients arbitrarily suspended any drug assumption. The possible significance and implications of these findings are discussed.

show abstract

“…Blood-sampling technique is an important variable in this method. Low plate1et:aggregate ratios have been found both in diabetics with (Preston et al 1978) and without (Davis et al 1982) vascular disease. 'Spontaneous' aggregation has also been studied in platelet-rich plasma or whole blood in vitro using a variety of techniques, mostly involving agitation by stirring.…”

Section: Platelet Function In Diabetes Mellitusmentioning

confidence: 98%

Nutrition and platelet function in atherogenesis

Betteridge

1987

Proc. Nutr. Soc.

View full text Add to dashboard Cite

Platelet Aggregate Ratio in Diabetes mellitus

Cited by 14 publications

References 11 publications

Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects

Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects

In vivo Platelet Activation in Lower Limbs Thrombophlebitis

Nutrition and platelet function in atherogenesis

Contact Info

Product

Resources

About